Advancements and Challenges of Gamma Delta (γδ) T Cell- and Invariant Natural Killer T (iNKT) Cell-Based Cancer Immunotherapies

Kawaljit Kaur^*
ImmuneLink, LLC, Riverside, CA 92508, USA
* Corresponding Author: Kawaljit Kaur. Email: email
(This article belongs to the Special Issue: The Role of γδ T Cells and iNKT Cells in Cancer: Unraveling Molecular Mechanisms and Therapeutic Potential)

BIOCELL https://doi.org/10.32604/biocell.2025.073252

Received 14 September 2025; Accepted 30 October 2025; Published online 21 November 2025

Download PDF

Abstract

Gamma delta (γδ) T cells and invariant natural killer T (iNKT) cells are unconventional T cells with limited T cell receptor (TCR) diversity. Both can recognize lipid or non-peptide antigens, often through cluster of differentiation 1d (CD1d), rapidly produce cytokines, express natural killer (NK) cell markers, and are mainly found in mucosal and barrier tissues. Acting as a bridge between innate and adaptive immunity, they show great promise for cancer immunotherapy. Developing γδ T and iNKT cells for treatment involves shared features like thymic origin, MHC-independent recognition, rapid cytotoxicity, low graft-vs.-host disease (GvHD) risk, ex vivo expansion, and genetic modification, making them suitable for adoptive cell therapies. While their mechanisms are similar, iNKT cells rely on CD1d-mediated antigen presentation, provided by CD1d-expressing antigen-presenting cells (APCs) or engineered cell lines, to activate their invariant TCR and expand effectively. Chimeric antigen receptors (CAR)-induced functional activations make these cell types viable alternatives to conventional cell-based or CAR-T therapies with additional safety benefits. Early clinical trials have shown encouraging results, and their completion will confirm their potential for future treatments. This review explores the biology and mechanisms of γδ T and iNKT cells, focusing on how APCs, cytokines, feeder cells, and CARs contribute to boosting their cytotoxic function, cytokine production, and expansion, enhancing their promise as cancer immunotherapies. It also explores the advancements and challenges in developing γδ T and iNKT cell-based immunotherapies, with preclinical and early clinical outcomes offering promising insights.

Keywords

Gamma delta (γδ) T cells; invariant natural killer T (iNKT) cells; immunotherapy; cancer; feeder cells; K562; cluster of differentiation 1d (CD1d) molecule

Downloads
- Full-Text PDF
Citation Tools
- BibTex
- EndNote
- RIS

1034

View
294

Download
1

Like

Chrysophanol inhibits the progression of gastric cancer by activating nod-like receptor protein-3
BINFEN HOU, LI ZHAO, T IANHAO...
The transcriptome analysis of cleft lip/palate-related PTCH1 variants in GMSM-K cells show carcinogenic potential
MINGZHAO LI, QIAN ZHANG, WENBIN...
Quercetin induced HepG2 cells apoptosis through ATM/JNK/STAT3 signaling pathways
WANTONG LIU, DANYANG CHEN, JINGYAO...
A double-edged sword: The HBV-induced non-coding RNAs alterations in hepatocellular carcinoma
TIANXING LIU, HONGYAN DIAO
Schisandrin B exerts anticancer effects on human gastric cancer cells through ROS-mediated MAPK, STAT3, and NF-κB pathways
TIANZHU LI, YU ZHANG, TONG ZHANG,...

Advancements and Challenges of Gamma Delta (γδ) T Cell- and Invariant Natural Killer T (iNKT) Cell-Based Cancer Immunotherapies

Abstract

Keywords

1034

294

1

Further Information

Guidelines

Follow Us

Join Us

Contact Us

WhatsApp:

Share Link